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HLA-B*13:01-positive patients in Thailand can develop frequent co-trimoxazole
hypersensitivity reactions. This study aimed to characterize drug-specific T cells from
three co-trimoxazole hypersensitive patients presenting with either Stevens-Johnson
syndrome or drug reaction with eosinophilia and systemic symptoms. Two of the
patients carried the HLA allele of interest, namely HLA-B*13:01. Sulfamethoxazole and
nitroso sulfamethoxazole specific T cell clones were generated from T cell lines of co-
trimoxazole hypersensitive HLA-B*13:01-positive patients. Clones were characterized for
antigen specificity and cross-reactivity with structurally related compounds by measuring
proliferation and cytokine release. Surface marker expression was characterized via flow
cytometry. Mechanistic studies were conducted to assess pathways of T cell activation in
response to antigen stimulation. Peripheral blood mononuclear cells from all patients were
stimulated to proliferate and secrete IFN-g with nitroso sulfamethoxazole. All
sulfamethoxazole and nitroso sulfamethoxazole specific T cell clones expressed the
CD4+ phenotype and strongly secreted IL-13 as well as IFN-g, granzyme B and IL-22.
No secretion of IL-17 was observed. A number of nitroso sulfamethoxazole-specific
clones cross-reacted with nitroso dapsone but not sulfamethoxazole whereas
sulfamethoxazole specific clones cross-reacted with nitroso sulfamethoxazole only. The
nitroso sulfamethoxazole specific clones were activated in both antigen processing-
dependent and -independent manner, while sulfamethoxazole activated T cell responses
via direct HLA binding. Furthermore, activation of nitroso sulfamethoxazole-specific,org April 2021 | Volume 12 | Article 6585931
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Frontiers in Immunology | www.frontiersin.but not sulfamethoxazole-specific, clones was blocked with glutathione. Sulfamethoxazole
and nitroso sulfamethoxazole specific T cell clones from hypersensitive patients were
CD4+ which suggests that HLA-B*13:01 is not directly involved in the iatrogenic disease
observed in co-trimoxazole hypersensitivity patients.Keywords: co-trimoxazole, drug hypersensitivity, human leukocyte antigen, sulfamethoxazole, T cellINTRODUCTION
Co-trimoxazole (CTX) is a combination drug consisting of
trimethoprim (TMP) and sulfamethoxazole (SMX). It is
commonly used for treatment of urinary tract infections due to
E. coli, Klebsiella and Enterobacter spp. and also suitable for
gastrointestinal infections against E. coli, Shigella spp. and
Salmonella typhi. It is the drug of choice for the treatment
and prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in
the Human Immunodeficiency Virus (HIV) patients (1).
Approximately 1 to 3% of CTX prescribed HIV-uninfected
patients develop mild to serious skin reactions including
erythema multiforme, Stevens–Johnson syndrome (SJS), toxic
epidermal necrolysis (TEN) and drug rash with eosinophilia and
systemic symptoms (DRESS), whereas such reactions occurred in
about 40 to 80% of HIV-infected patients (2–4).
Several forms of drug hypersensitivity reactions are associated
with the carriage of human leukocyte antigens (HLA). Presentation
of drug, drug modified or altered peptide sequences (due to drugs
binding deep within the peptide binding groove) on the surface of
HLA to T cell lymphocytes may stimulate an immune response via
triggering of the T cell receptor (TCR) (5, 6). Co-trimoxazole-
induced SJS/TEN is associated with HLA-B*15:02, HLA-C*06:02,
and HLA-C*08:01 in Thai population (7) and HLA-B*38
in Europeans (8). Interestingly, our previous case-control
study demonstrated that HLA-B*13:01 is associated with co-
trimoxazole-induced DRESS in Thai population, while co-
trimoxazole-induced SJS/TEN was associated with HLA-B*15:02
(9). This observation on co-trimoxazole-induced SJS/TEN was
consistent with previous studies (7). However, not all patients
with an HLA risk allele developed reactions. As T cells are
thought to be involved in the molecular pathogenesis of many
forms of severe cutaneous adverse reactions (10–12), a global TCR
repertoire analysis in HLA-B*15:02 positive patients with
carbamazepine-induced SJS/TEN was studied and clearly
demonstrated that restricted TCR usage of drug-specific T cells
participated in the development of a reaction (8). Moreover, the
analysis of TCR Vb repertoire of HLA-B*57:01 positive patients
susceptible to abacavir hypersensitivity illustrated polyclonal TCR
usages recognize the drug-HLA complex, then driving the T cell
activation (13–15).
T cell activation and the release of effector molecules depends
on drug (antigen) recognition by T cell receptors located on the
cell surface. The T cell receptor receives signals from the drug,
peptide and HLA protein which form a complex and are
displayed on the surface of antigen presenting cells. Thus, this
study aimed to characterize the T cell responses fromThai patients
with co-trimoxazole-induced drug rash with eosinophilia andorg 2systemic symptoms. The assessment of specific T cell responses
is essential to better understand the nature of the immune
response induced and disease progression.MATERIALS AND METHODS
Study Population
Co-trimoxazole-induced Stevens–Johnson syndrome (SJS) and
drug reaction with eosinophilia and systemic symptoms
(DRESS) patients were recruited from Ramathibodi Hospital
and Srinagarind Hospital between 2018 and 2019. All of the
patients studied were HIV negative. Reactions were assessed by
two dermatologists or allergists who reviewed photographs,
pathological slides, clinical morphology and medical records.
SJS is defined as skin detachment of BSA < 10%, the clinical
features of DRESS follow criteria from RegiSCAR and is defined
as patients presenting with fever, maculopapular rash with
internal organ involvement, and hematologic abnormalities.
We evaluated co-trimoxazole was the causative drug of SJS or
DRESS using Naranjo algorithm (16), the score of the algorithm
of drug causality for epidermal necrolysis (ALDEN) (17). The
cases defined as possible, probable and definite were recruited in
this study. The blood samples were collected after the patients
recovered from the reaction between 2-5 years. The lymphocyte
transformation test (LTT) and IFN-g ELISpot was also performed
on patient’s PBMC to identify the presence of circulating drug
responsive T cells.
The study was performed according to the approval by the
Ramathibodi Hospital and Srinagarind Hospital ethical review
board, and both informed and written consent forms were
obtained from all the participants.
DNA Extraction and HLA Genotyping
The DNA was extracted from PBMC by DNA extraction
automated MagNA Pure Compact (Roche Diagnostics GmbH,
Germany). The concentration of genomic DNA for all individuals
was assessed by using NanoDrop 2000 for measuring the genomic
DNA as well as purity with dynamic range around 220 to 750 nm.
Wavelength at 260 nm is suitable for measuring the genomic DNA
and at 280 nm was used to evaluate contaminated protein in
the sample.
HLA alleles were genotyped using sequence-specific
oligonucleotides (PCR-SSOs). In brief, the diluted DNA sample
obtained from each patient were amplified polymerase chain
reaction (PCR) by GeneAmp®PCR System 9700 (Applied
Biosystems, Waltham, USA). The PCR product was thenApril 2021 | Volume 12 | Article 658593
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polystyrene microspheres that had sequences complementary to
stretches of polymorphism within the target HLA alleles using
the Lifecodes HLA SSO typing kits (Immucor, West Avenue,
Stamford, USA). The amplicon-probe complex was then visualized
using a colorimetric reaction and fluorescence detection technology
by the Luminex®IS 100 systems (Luminex Corporation, Austin,
Texas, USA). Analysis of the HLA alleles was performed using
MATCH IT DNA software version 3.2.1 (One Lambda, Canoga
Park, CA, USA).
Chemicals, Cell Culture, Generation
of EBV
Dapsone (DDS), SMX and TMP were purchased from Sigma-
Aldrich, (Buchs, Switzerland). EBV-transformed autologous B
lymphoblastoid cell lines (B-LCLs) were used as antigen-
presenting cells (APCs). PBMCs were isolated from co-
trimoxazole induced DRESS carrying HLA-B*13:01 using Ficoll
density gradient centrifugation. For APC generation, the
supernatant of B95.8 cells was filtered and added to 5x106
PBMCs, then 1 µg/mL cyclosporin A (CSA) was added. The
PBMC were then incubated in 5% CO2 incubator at 37°C
overnight. The mixture was centrifuged at 1500 rpm for
10 minutes, then the cells were re-suspended in 2 mL culture
medium with CSA and transferred to a 24 well plate. Culture
medium consisted of RPMI 1640, 10% pooled fetal bovine serum
(FBS), HEPES buffer (25mM), L-glutamine (2mM), streptomycin
(100 µg/mL) and penicillin (100 U/mL). To maintain B cell
transformation, medium and CSA were replaced twice a week
for 3 weeks. Eventually the transformed B cell lines were
maintained with medium in the absence of CSA before being
transferred to a flask. These cells were used as a ready supply of
immortalized autologous APC.
Generation and Characterization of Drug
Specific T Cell Clones
T cell lines were generated by culturing PBMCs with dapsone
(DDS, 125 µM), nitroso-dapsone (DDS-NO, 10 µM),
sulfamethoxazole (SMX, 1 mM) and nitroso-sulfamethoxazole
(SMX-NO, 20 µM) in medium for 14 days (37°C; 5% CO2) and
media containing IL-2 (2 µL/mL) was added to maintainFrontiers in Immunology | www.frontiersin.org 3proliferation on day 6 and 9. Culture medium consisted of
RPMI 1640, 10% pooled heat inactivated human AB serum,
HEPES buffer (25 mM), L-glutamine (2 mM), transferrin (25
µg/mL), streptomycin (100 µg/mL), penicillin (100 U/mL). T cells
clones were generated by serial dilution (18). The characterization
of T cell clones was conducted in terms of cellular surface marker
expression, HLA mismatch assay, HLA restriction assay, antigen
presenting cell pulsing and fixation assay, the effect of glutathione
and enzyme inhibitor; methimazole (an inhibitor of peroxidases
and flavin–mono-oxygenases; Meth) and 1-aminobenzotriazole
(a nonselective suicide inhibitor; ABT). Detailed methods are
provided as Supplementary S1 and Supplementary Figure 1.RESULTS
Clinical Manifestation of Patients and In
Vitro Activation of Patient’s Peripheral
Blood Mononuclear Cells
Three patients that developed CTX-induced SJS and DRESS were
utilized in this study. The causality assessment and in vitro test of
the patients are shown in Table 1. PBMC from all patients were
stimulated to proliferate and secrete IFN-g with SMX-NO.
PBMC from one patient were also stimulated with SMX, the
parent compound. Additionally, PBMC from all patients
secreted IFN-g once PBMC were cultured with SMX. The
proliferation of PMBC from one patient was observed when
PBMC were cultured with nitroso-dapsone (DDS-NO), a
structurally-related compound (Supplementary Figure 2).
Generation and Characterization of Drug
Specific T Cell Clones
For BAC-02, two of forty-nine clones and three of sixty-four
clones were specific to SMX and SMX-NO, respectively. For
BAC-12, eight of thirty-two clones were specific to SMX-NO. No
specific clones were generated from BAC-08. Cellular surface
marker expression was assayed using flow cytometry. All SMX
and SMX-NO specific T cell clones expressed the CD4+
phenotype as shown in Table 2.
Twenty five percent of SMX-NO specific clones displayed
cross-reactivity with DDS-NO, a structurally-related drugTABLE 1 | Clinical characteristics, causality assessment and in vitro test of the patients with co-trimoxazole-induced SCARs.
Patient
ID




Naranjo score Alden score DRESS score
Score Remark Score Remark Score Remark
BAC-02 Male 27 Maculopapular rash: face and
extremities, abnormal liver function tests
28 DRESS + + 6 Probable N/A N/A 5 Probable
BAC-08 Female 25 Generalized dusky erythematous
patches with some vesicles on neck with
nikolsky’s sign on neck and upper chest
9 SJS + + 5 Probable 4 Probable N/A N/A
BAC-12 Female 44 Confluent maculopapular rash on trunk
and extremities, abnormal liver function
tests
30 DRESS + + 6 Probable N/A N/A 4 ProbableApril 2021 | Volume 12 | ArticlDRESS, drug reaction with eosinophilia and systemic symptoms; ELISpot, enzyme-linked immunospot; IFN-g, Interferon gamma; LTT, lymphocyte transformation test; N/A, not available;
SCARs, severe cutaneous adverse reactions; SJS, Stevens-Johnson syndrome.e 658593
Pratoomwun et al. T Cell Phenotypic Studiesmetabolite, but not SMX, whereas SMX specific clones cross-
reacted with SMX-NO only (Table 2 and Supplementary Figure 3).
High levels of IL-13 were detected from all T cell clones, while
some T cell clones weakly secreted IFN-g, granzyme B and IL-22.
Interestingly, no T cell clones secreted IL-17 (Figure 1).Frontiers in Immunology | www.frontiersin.org 4Activation of CD4+ Clones With SMX and
SMX-NO is HLA Class II Restricted
The proliferation of T cell clones to SMX-NO was blocked in the
presence of HLA class II blocking antibody (Figure 2A),
indicating that the proliferative response of CD4+ specific TTABLE 2 | Number, cellular phenotype and cross reactivity of drug-specific T cell clones.
Patients Total number of clones Number of specific clones Phenotype (%) Cross reactivity (%)
CD4 SMX SMX-NO DDS DDS-NO
BAC-02
- SMX 49 2 100 0 50 0 0
- SMX-NO 64 3 100 0 0 0 0
BAC-08
- SMX 9 0 – – – – –
- SMX-NO 47 0 – – – – –
BAC-12
- SMX 1 0 0 0 0 0
- SMX-NO 32 8 100 0 0 0 25April 2021 | Volume 12 | ArticDDS, dapsone; DDS-NO, nitroso dapsone; SMX, sulfamethoxazole; SMX-NO, nitroso sulfamethoxazole.
-, not done.FIGURE 1 | ELISpot images of cytokine secretion by SMX-NO and SMX specific T cell clones. TCCs (5x104) were cultured with irradiated autologous EBV-
transformed B-cells (1x104) in the presence or absence of SMX-NO (40 µM) or SMX (1 mM) in an ELISpot plate pre-coated for IFN-g, granzyme B, IL-13, IL-17 and
IL-22 for 48h (37˚C; 5% CO2). Following incubation, the plate was developed according to the manufactures instructions visualized by ELISpot AID reader.le 658593
Pratoomwun et al. T Cell Phenotypic Studiescells might be HLA class II restricted. Additionally, to investigate
the involvement of HLA-B*13:01 in the co-trimoxazole
hypersensitivity reaction, SMX-NO specific T cell clones were
cultured with EBV-transformed B cells from three other patients
carrying HLA-B*13:01 (P1-3), three patients EBVs carrying
HLA-B*57:01 (P4-6) and cells from three donors carrying
other alleles (not HLA-B*13:01 or -B*57:01, P7-9). Figure 2B
shows T cell clones were stimulate to proliferate in the presence
of SMX-NO and antigen presenting cell expressing a range of
HLA class I and II molecules.Frontiers in Immunology | www.frontiersin.org 5SMX-NO Binds Covalently to Antigen
Presenting Cells and Activates CD4+
T Cells Through Processing-Dependent
and Processing-Independent Manners
Eight SMX-NO specific clones were used to investigate pathways
of drug presentation. The proliferative response of four clones
was blocked when APC were fixed with glutaraldehyde. In
contrast, with the other four clones, T cell proliferative
responses were detected when the drug metabolite wasA
B
FIGURE 2 | The proliferative response of SMX-NO specific T cell clones. (A) T cell clones (5x104) were culture with autologous EBV-transformed B-cells (1x104)
and SMX-NO (40 µM) in the presence or absence of HLA class I and class II blocking antibodies for 48 hours (37°C, 5% CO2). Following incubation, [3H]-thymidine
(0.5 mCi) were added to measure proliferative response. (B) T cell activation of SMX-NO clones in the response of different HLA-B. T cell clones (5x104) were
cultured with SMX-NO (40 µM) and irradiated EBV-transformed B-cells (1x104) from 9 different patients carrying HLA-B*13:01 (P1-3), -B*57:01 (P4-6) and other
HLA-B (P7-9).April 2021 | Volume 12 | Article 658593
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stimulated to proliferate when APC pulsed with SMX-NO for 1
or 16 h were added to the assay as a source of antigen (Figure 3).
The strength of the induced response was similar to that
observed with the soluble drug metabolite.
In separate experiments, the SMX-NO specific T cell clones
were incubated with autologous APC and SMX-NO in the
presence and absence of glutathione (GSH), which functions to
reduce SMX-NO protein binding via quenching the metabolites
reactivity. The proliferative response of SMX-NO specific clones
reduced when GSH was cultured with soluble SMX-NO.Frontiers in Immunology | www.frontiersin.org 6Furthermore, proliferative responses were inhibited when GSH
was included in a 2h APC pulsing experiments (Figure 4A). T cell
clones abrogated by the 2 h-pulse with GSH (Figure 4A).
Activation of SMX-NO specific clones was not altered in the
presence of enzyme inhibitors ABT and methimazole (Figure 4B).
SMX Specific Clones Are Activated
Through a Direct HLA Binding Interaction
The SMX specific T cell clone was stimulated to proliferate in the
presence of soluble drug, but not with APC pulsed with SMX for
1 or 16h (Figure 5). The T cell proliferative response wasA
B
FIGURE 3 | SMX-NO stimulates specific T cell via antigen processing-dependent and processing-independent pathways. Autologous EBV-transformed B-cells
(1x104) were incubated with T cell clones (5x104) in the presence or absence of SMX-NO (40 µM) for 1 and 16 hours. For fixation assay, SMX-NO specific clones
(5x104) were cultured with either irradiated or glutaraldehyde-fixed autologous EBV-transformed B-cell (1x104) in the presence of SMX-NO (40 µM) for 48 hours
(37˚C; 5% CO2). [
3H]-thymidine (0.5 mCi) incorporation was used to measure proliferative response. (A) SMX-NO T cell clones are stimulated in the presence of
glutaraldehyde-fixed APC (B) Glutaraldehyde-fixed APC reduced the proliferative response of SMX-NO T cell clones.April 2021 | Volume 12 | Article 658593
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glutaraldehyde-fixed APC. The presence of GSH and ABT had
no effect on activation of the SMX specific T cell clone with
soluble drug.DISCUSSION
Several studies have shown a strong association between expression
of a particular HLA allele and an increased susceptibility to drug
hypersensitivity reactions. For example, HLA-B*13:01 is associated
with dapsone-induced hypersensitivity reactions among leprosy
patients and non-leprosy patients in Chinese and Thai (19–21).
Other genetic associations between medication-induced cutaneous
adverse reactions and specific HLA alleles have been identified in
various populations, including HLA-B*57:01 and abacavir in
Western Australian and North American populations (22, 23),Frontiers in Immunology | www.frontiersin.org 7HLA-B*15:02 and carbamazepine in Han Chinese and Thai
populations (24–27), HLA-A*31:01 and carbamazepine and
HLA-A*32:01 and vancomycin in European populations (28, 29)
and HLA-B*58:01 and allopurinol in Han Chinese, Japanese and
Thai populations (30–32). However, known associations between
expression of an HLA risk allele and co-trimoxazole
hypersensitivity are limited. Only one study by Kongpan et al.
(7) demonstrated that HLA-B*15:02, HLA-C*06:02, and HLA-
C*08:01 were significantly associated with co-trimoxazole-
induced SJS/TEN. Recently, a genetic study showed that the
HLA-B*13:01 allele is associated with co-trimoxazole-induced
DRESS in Thai population (9).
In this study, T cells were characterized from co-trimoxazole
hypersensitive patients to 1) define the nature of the antigenic
determinant that activates T cells, 2) determine pathways of
drug-specific T cell activation and 3) explore whether drug HLA-
B*13:01 binding is directly involved in the T cell response. TheA
B
FIGURE 4 | The proliferative response of SMX-NO and SMX specific T cell clones in the presence of glutathione (GSH) and enzyme inhibitors. (A) Autologous EBV-
transformed B-cells (1x104) were culture with T cell clones (5x104) in the presence or absence of GSH (1 mM). For pulsing EBVs, T cell clones (5x104) were culture
with and without 2 h pulsed-antigen presenting cells (1x104) in the presence or absence of SMX-NO (40 µM) or SMX (1 mM) for 48 hours (37˚C; 5% CO2). After
incubation, [3H]-thymidine (0.5 mCi) were added to measure proliferative response. (B) 16 h-enzyme inhibitor pulsed EBVs (1x104) were incubated with T cell clones
(5×104) for 48 hours (5% CO2 at 37˚C). For normal condition, Autologous EBV-transformed B-cells were cultured with T cell clones and enzyme inhibitors for 1 hour
(5% CO2 at 37˚C) and 40 µM nitroso sulfamethoxazole. Following incubation, the plate was developed according to the manufactures instructions visualized by
ELISpot AID reader. Methimazole; Meth, 1-aminobenzotriazole; ABT.April 2021 | Volume 12 | Article 658593
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causative agent that can be performed during the recovery phase
of a hypersensitivity reaction (33, 34). A small cohort of CBZ-
hypersensitive patients demonstrated that the lymphocyte
transformation test was positive in only the hypersensitive
patients (35), while in b-lactam hypersensitive patients with
cystic fibrosis, the lymphocyte transformation test had a
sensitivity of approximately 75% (36). In this study, three
patients’ peripheral blood mononuclear cells were found to
proliferate in the presence of sulfamethoxazole and/or its
reactive nitroso metabolite. IFN‐g PBMC ELISpot was used to
confirm the positive result (Supplementary Figure 2). Two SMX
and eleven SMX-NO specific T cells were generated from T-cell
lines generated from two of the hypersensitive patients. Both
patients carried HLA-B*13:01. The SMX-NO specific clones
cross-reacted with the structurally related compound, nitroso
dapsone (DDS-NO), which demonstrates the importance of the
reactive nitroso functionality in the T cell response. A clinical
cross-reactivity rate between co-trimoxazole and dapsone has
been estimated to be approximately 22% and this may be due to
the cross-reactivity of the metabolite-responsive T cells (37).
Dapsone is related to SMX in that it contains an aromatic amine
and a sulfone function, but the drugs differ in terms of their
side-chains.
All of the SMX and SMX-NO specific T cell clones expressed
a CD4+ phenotype which concordant to previous studies (38,
39). Immunohistochemical studies have shown that the cell
infiltrate in maculopapular exanthema predominantly consists
of CD4+ T cells (40, 41), whereas a predominance of epidermal
CD8+ T cells is seen drug-induced bullous exanthem (42).
Previous studies have revealed that drug-specific T cells secrete
various cytokines including IFN-g, IL-13, IL-22 (43, 44). The
present study showed that both SMX and SMX-NO specific TFrontiers in Immunology | www.frontiersin.org 8cells secreted high levels of IL-13 along with lower levels of IL-22,
IFN-g and granzyme B secretion. However, IL-17 secretion from
the clones was not observed. Eosinophilia is naturally reported in
DRESS. Under inflammatory conditions, IL-13 is excreted by
eosinophils which drives inflammatory responses and is typically
associated with allergic inflammation (45–47).
Genetic association studies have shown a significant
association between HLA-B*13:01 and co-trimoxazole-induced
DRESS in patients with HIV infection (9). These data suggest
that the causative drug might interact with the HLA-B*13:01
protein to activate CD8+ T cells in hypersensitive patients. Co-
trimoxazole hypersensitivity is observed at a much lower
frequency in patients without HIV infection. The reason for
this is unclear, but may relate to a redox imbalance in patients
with HIV infection, or altered metabolism, that leads to the
formation of higher levels of sulfamethoxazole protein adducts
(9, 48). A significant higher frequency of the HLA-B*13:01-
C*03:04 haplotype was detected in co-trimoxazole-induced
DRESS in the Thai population (9) and this is in linkage
disequilibrium (LD) in Chinese (49) and Korean populations
(50). Furthermore, these two alleles are also in LD with a HLA
class II allele, namely HLA-DRB1*12:02 (50).
Somewhat surprisingly, the clones identified as drug-
responsive in this study were CD4+ and T cell activation was
diminished upon the blockade of HLA class II. This finding is in
agreement with the study of Ogese and colleagues (38), which
explored SMX T-cell responses in European patients, with
hypersensitivity of mild to moderate severity, that were
unlikely to express HLA-B*13:01. Ogese et al. demonstrated
that the response of SMX-NO specific CD4+ T cells was
restricted to the HLA-DQ allele, indicating that HLA class II
plays an important role in the T cell activation in patients
presenting with differing reaction phenotypes. In future studiesFIGURE 5 | T cell activation in response to antigen stimulation of SMX specific clone. Autologous EBV-transformed B-cells (1x104) were incubated with SMX (1 mM)
for 1 and 16 hours, and then incubated with T cell clones (5x104) after three washing steps. For fixation assay, SMX specific T cell clones (1x104) were cultured with
either irradiated or glutaraldehyde-fixed autologous EBV-transformed B-cell (5x104) in the presence of SMX (1 mM) for 48 hours (37°C, 5% CO2). After incubation,
[3H]-thymidine (0.5 mCi) incorporation was used to measure proliferative response.April 2021 | Volume 12 | Article 658593
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expressed by drug-responsive T-cell clones and then determine
their frequency in hypersensitive and tolerant patient PBMC.
The availability of SMX and SMX-NO responsive T cells
allowed us to probe pathways of drug presentation by the HLA
class II molecules. The SMX-NO responsive clones were
stimulated to proliferate with APC pulsed with the drug
metabolite for 1- and 16-hours. These data demonstrate that
formation of a stable complex between the drug metabolite and
antigen presenting cells is important for T cell activation. These
data are concordant with Schnyder et al. which demonstrated the
responsive T cell clones from SMX hypersensitive patients
recognized covalently bound SMX-NO (39). The proliferative
response of 5 out of 9 of the SMX-NO specific T cell clones
analyzed was abolished APC were fixed with glutaraldehyde.
This indicates that the T cell activation is dependent upon
antigen processing and that the T cells are likely activated with
drug-modified peptides. On the contrary, fixed antigen
presenting cells had little effect on the activation of the
remaining 4 clones. These clones are presumably activated
when SMX-NO binds directly with surface peptides embedded
within the HLA class II proteins. Finally, a SMX specific clone,
SMX-43, was subjected to the same experiments. This clone was
stimulated to proliferate with soluble drug in the presence of
irradiated and fixed APC, while SMX-pulsed APC did not
activate the T-cells. Direct interactions of drugs (p-i model) are
not stable and washing the cells abolishes reactivity. Previous
studies suggest that SMX may interact directly with either HLA-
peptide complex (p-i HLA) or T cell receptors (p-i TCR) which
can induce T cell activation (51, 52).
The tripeptide glutathione functions to prevent SMX-NO
from covalently modifying proteins via quenching its reactivity
(53, 54). Addition of glutathione to SMX-NO specific T cells
blocked the induced proliferative response of the drug
metabolite, whereas glutathione had no effect on the activation
of clones with SMX (43, 53).
In conclusion, the generation of SMX and SMX-NO specific
T-cell clones from co-trimoxazole hypersensitive patients suggests
an immune mediated basis for the hypersensitivity reactions
observed in individuals expressing HLA-B*13:01. The clones were
CD4+ and activation was HLA class II-restricted indicating that
HLA-B*13:01 was not directly involved in the disease pathogenesis.DATA AVAILABILITY STATEMENT
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three hypersensitive patients (A) hypersensitive patients’ PBMCs (1.5x106) were
cultures with SMX (1 and 2 mM), SMX-NO (10 and 20 µM), TMP (10 and 25 µM),
DDS (125 and 250 µM) and DDS-NO (5 and 10 µM) for 6 days (37°C, 5% CO2).
Following incubation, [3H]-thymidine (0.5 mCi) were added to measure proliferative
response. (B) PBMCs (5x106) were cultured in the presence of SMX (1mM), SMX-
NO (20 µM), DDS (125 µM) and DDS-NO (10 µM) for 48 hours (37°C, 5% CO2).
Following incubation, the plate was developed according to the manufactures
instructions visualized by ELISpot AID reader.
Supplementary Figure 3 | Cross-reactivity of SMX-NO specific T cell clones.
Autologous EBV-transformed B-cells (1x104) were incubated with SMX-NO specific
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